Sort   by:  
 Page size 
TranscriptomicsMolecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
SN-38 resistant breast cancer cell lies (MCF-7 and MDA-MB-231) were established by stepwise increasing the concentration of SN-38. Gene expression profiling was performed on parental (sensitive) MCF-7 and parental (sensitive) MDA-MB-231 cell lines and their respective SN-38 resistant cell lines. For...
ORGANISM(S): Homo sapiens 
2016-01-05 | E-MTAB-3224 | biostudies-arrayexpress
TranscriptomicsTime course analysis of human colorectal cancer organoid treatment with Sacituzumab Govitecan (SG) or untargeted control IgG1-SN-38
Human colorectal cancer organoids were treated with the TROP2-targeting antibody-drug conjugate Sacituzumab Govitecan (SG) or non-targeting control IgG1-SN-38. Samples were harvested at different time points under treatment {0h, 3h, 6h, 9h, 12h} as well as after drug washout at 12 h on the following...
ORGANISM(S): Homo sapiens 
2026-04-01 | E-MTAB-16843 | biostudies-arrayexpress
ClinicalLiposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal SN-38, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well liposomal SN-38 works in treating patients with metastatic colore...
2027849 | ecrin-mdr-crc
TranscriptomicsSN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma
Anti-programmed cell death 1 (PD-1) therapy shows definite but modest activity in patients with advanced/metastatic HNSCC. Preliminary evidence suggests that SN-38, an activated form of irinotecan that activates the transcription factor FoxO3a, may suppress the expression of PD-L1 in breast and ovar...
ORGANISM(S): Mus musculus 
2023-01-11 | GSE222450 | GEO
GenomicsSN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma
SN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma
PRJNA922128 | ENA
ProteomicsTotal and phosphoproteome analysis of effects of topoisomerase 1 and ATR inhibitors in small cell lung cancer nuclei
Total and phosphoproteome analysis of effects of topoisomerase 1 (SN-38) and ATR (M1774) inhibitors in small cell lung cancer. Experiments performed in nuclear extract. See MetaData for more information.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-02-21 | MSV000091336 | MassIVE
Genomics5-FU and SN-38 impact on colon microbiota
5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro
PRJEB19934 | ENA
UnknownPLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
Not available
S-EPMC11187204 | biostudies-literature
TranscriptomicsTime course analysis of human colorectal cancer liver metastasis models under Sacituzumab Govitecan (SG) treatment or untargeted control
Human colorectal cancer organoids were injected intrasplenically to form liver metastasis in mice were treated with the TROP2-targeting antibody-drug conjugate Sacituzumab Govitecan (SG) or non-targeting control IgG1-SN-38 (ADC). Tumors were harvested at different time points: 0 h, 6 h, 24 h, 48 h,...
ORGANISM(S): Homo sapiens 
2026-04-01 | E-MTAB-16849 | biostudies-arrayexpress
UnknownSN-38-indoximod conjugate: carrier free nano-prodrug for cancer therapy.
Not available
S-EPMC11875466 | biostudies-literature
Sort   by:  
 Page size